Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Intravenous iron therapy among patients with heart failure and iron deficiency: An updated meta-analysis of randomized controlled trials
Heliyon, Volume 9, No. 6, Article e17245, Year 2023
Notification
URL copied to clipboard!
Description
Background: Randomized clinical trials (RCTs) evaluating the role of intravenous (IV) iron administration in patients with heart failure (HF) and iron deficiency (ID) have yielded inconsistent results. Methods: Electronic search of MEDLINE, EMBASE and OVID databases was performed until November 2022 for RCTs that evaluated the role of IV iron administration in patients with HF and ID. The main study outcomes were the composite of HF hospitalization or cardiovascular mortality, and individual outcome of HF hospitalization. Summary estimates were evaluated using random effects model. Results: The final analysis included 12 RCTs with 3,492 patients (1,831 patients in the IV iron group and 1,661 patients in the control group). The mean follow-up was 8.3 months. IV iron was associated with a lower incidence in the composite of HF hospitalization or cardiovascular mortality (31.9% vs. 45.3%; relative risk [RR] 0.72; 95% confidence interval [CI] 0.59–0.88) and individual outcome of HF hospitalization (28.4% vs. 42.2; RR 0.69; 95% CI 0.57–0.85). There was no significant difference between both groups in cardiovascular mortality (RR 0.88; 95% CI 0.75–1.04) and all-cause mortality (RR 0.95; 95% CI 0.83–1.09). IV iron was associated with lower New York Heart Association class and higher left ventricular ejection fraction (LVEF). Meta-regression analyses showed no effect modification for the main outcomes based on age, hemoglobin level, ferritin level or LVEF. Conclusion: Among patients with HF and ID, IV iron administration was associated with reduction in the composite of HF hospitalization or cardiovascular mortality and driven by a reduction in HF hospitalization. © 2023 The Author(s)
Authors & Co-Authors
Hamed, Mohamed
United States, Boca Raton
Florida Atlantic University
Elseidy, Sheref Abdelgawad Hassan
United States, Rochester
Rochester General Hospital
Thakker, Ravi A.
United States, Galveston
The University of Texas Medical Branch at Galveston
Mansoor, Hend
United States, Lexington
University of Kentucky
Khalili, Houman
United States, Hollywood
Memorial Healthcare System
Mamas, Mamas Andreas
United Kingdom, Keele
Keele University
Kumbhani, Dharam Jaydeep
United States, Dallas
Ut Southwestern Medical Center
Elgendy, Islam Y.
United States, Lexington
University of Kentucky
Elbadawi, Ayman
United States, Dallas
Ut Southwestern Medical Center
Statistics
Authors: 9
Affiliations: 9
Identifiers
Doi:
10.1016/j.heliyon.2023.e17245
ISSN:
24058440
Research Areas
Noncommunicable Diseases
Study Design
Randomised Control Trial
Cohort Study
Study Approach
Systematic review